首页> 外文期刊>European psychiatry: the journal of the Association of European Psychiatrists >Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis
【24h】

Is it worth assessing progress as early as week 2 to adapt antidepressive treatment strategy? Results from a study on agomelatine and a global meta-analysis

机译:是否有必要在第2周就评估抗抑郁治疗策略的进展情况?阿戈美拉汀研究和全球荟萃分析的结果

获取原文
获取原文并翻译 | 示例
       

摘要

Context: A delay of 4-8. weeks before modifying the prescribed antidepressant treatment is usually proposed when incomplete treatment response is observed. A number of studies nevertheless proposed that the lack of early improvement (usually 20% decrease of severity at week 2) is predictive of the absence of subsequent treatment response, potentially saving weeks of inadequate treatment, but with no information for non-interventional studies devoted to outpatients. Method: Two thousand nine hundred and thirty-eight outpatients with major depressive disorder were included in a multicentre, non-interventional study, assessing at inclusion, week 2 and week 6, mood (QIDS-C, CGI, PGI and VAS) sleep (LSEQ) and functionality (SDS). All metrics at week 2 were tested for their capacity to predict response (and then remission) at week 6, all patients being treated by agomelatine. A meta-analysis of all studies (n= 12) assessing the predictive role of improvement at week 2 was also performed, assessing specific effect size of published studies and the weight of the different parameters they used. Results: The QIDS-C and the CGI-I were the only instruments with an area under the curve over 0.7, with different cut-offs for treatment response and remission. A decrease of more than five points at the QIDS-C had the highest positive predictive value for treatment response, and a CGI-I over three had the highest negative predictive value, which would favour relying on the clinicians for warning (too high CGI-I), and on instruments for confidence (favourable decrease of the QIDS-C). The meta-analysis of all studies also detected a large effect size of early improvement, stressing how rating week 2 severity could be beneficial in clinical practice. Conclusions: Previous reports stressing the interest of an assessment at week 2 were reinforced by the present results, which also defined more accurately what could be the most appropriate cut-offs, and how combining these early results could be more effective.
机译:上下文:延迟4-8。当观察到不完全的治疗反应时,通常建议在修改处方的抗抑郁药治疗前几周。尽管如此,许多研究提出,缺乏早期改善(通常在第2周时严重程度降低20%)可预示后续治疗反应的缺乏,可能节省数周的治疗不足,但没有专门研究非干预性研究的信息给门诊病人。方法:一项多中心非干预性研究纳入了293名重度抑郁症门诊患者,在入选时,第2周和第6周进行评估(QIDS-C,CGI,PGI和VAS)的睡眠( LSEQ)和功能(SDS)。测试了第2周的所有指标的预测第6周的反应(然后缓解)的能力,所有患者均接受阿戈美拉汀治疗。还对所有研究(n = 12)进行了荟萃分析,评估了第2周改善的预测作用,评估了已发表研究的具体疗效大小以及所用不同参数的权重。结果:QIDS-C和CGI-I是仅有的曲线下面积大于0.7的仪器,其治疗反应和缓解的截止值不同。 QIDS-C下降超过5点具有最高的治疗预测阳性预测值,而CGI-I下降3则具有最高的阴性预测值,这将有利于依靠临床医生进行警告(CGI值过高) I)和信心工具(QIDS-C的有利减少)。所有研究的荟萃分析还发现了早期改善的巨大影响力,强调了评估第2周严重程度在临床实践中可能是有益的。结论:以前的报告强调了在第2周进行评估的兴趣,现在的结果进一步加强了该结果,该报告还更准确地定义了什么是最合适的分界点,以及如何将这些早期结果相结合会更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号